Acute Lymphocytic Leukemia, Leukemia
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
Eligible for screening study DCP 001
Confirmation of Tolerability Phase and slot reservation completed and study currently open to Phase III enrollment as of 06/12/2018. See Section 4.4 for registration and randomization instructions.